Amended Current Report Filing (8-k/a)
July 10 2015 - 5:19PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 9, 2015
CORTEX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S
Employer
Identification
No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory
Note
On
July 9, 2015, Cortex Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original
Report”) that furnished, as Exhibit 99.1, a collection of slides that the Company intended to use in connection with its
attendance at the National Angel-VC Summit & Growth Capital Forum being hosted at the Yale Club New York on July 9, 2015.
Among other things, those slides referred to a clinical study of the compound dronabinol, which is being conducted by the University
of Illinois (the “Study”). The Company attended the forum as scheduled, but noted that the estimated completion for
the Study was incorrectly noted on slide 33 as 3Q2015, instead of the correct period, 2Q2016.
Accordingly,
attached as Exhibit 99.1 to this Current Report on Form 8-K/A are revised slides (the “Revised Slides”) that include
the corrected date on slide 33. The full slide deck, with the updated slide 33, will also be available on the Company’s
web-site.
The
remainder of the information provided with the Original Report remains unchanged.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: July 10, 2015 |
CORTEX PHARMACEUTICALS, INC. |
|
|
(Registrant) |
|
|
|
|
By: |
/s/
Arnold S. Lippa |
|
|
Arnold S. Lippa
President and Chief
Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
|
Exhibit
Description |
|
|
|
99.1 |
|
Revised
Slides amending certain slides furnished as Exhibit 99.1 to the Company’s Current
Report on Form 8-K filed July 9, 2015*
|
* Furnished herewith
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024